瑞豐新材(300910.SZ):2020年度淨利預增80%-100%
格隆匯1月18日丨瑞豐新材(300910.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤1.77億元-1.97億元,同比增長80%-100%。業績變動原因如下:
隨着公司的市場美譽度與產品競爭力的持續提升,2020年雖有新冠疫情的影響,但公司境內外銷售仍取得較大幅度的增長;同時公司持續推進技術迭代進步、銷售結構調整與複合劑產品級別提升,規模效應逐步顯現,加之主要原材料的價格在2020年度處於相對低位等因素影響,公司的盈利能力也實現較大幅度地提升。銷量增長迭加盈利能力的提升,公司2020年度的經營業績取得大幅增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.